A Phase III, randomized, double-blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in cystic fibrosis patients

Administered By

Awarded By

Contributors

Start/End

  • November 20, 2017 - December 31, 2020